Sentry expands platform offering
Sentry Group has moved to further expand its Compass-labelled platform offering via a partnership with OneVue which will build on its previously-announced relationship with Netwealth.
The financial services group said the deals with OneVue and Netwealth would be launched under the Compass private label and would mean Sentry's network of non-aligned advisers would gain access to a suite of separately managed accounts (SMA) solution managed by FPI Investments.
According to Sentry, four platform solutions have now been brought within Compass private label offering and compliment the firm's existing arrangements with HUB24 and Asgard.
Commenting on the developments, Sentry Group Executive Chairman and chief executive, Murray Hills said that by expanding its Compass private label range of platforms, Sentry was now one of the few licensee groups in Australia offering a genuine choice of platform solutions to its network of advisers.
He said that, in addition, the suite aimed to provide practice efficiency benefits for its advisers and reduce the compliance burden required in managing client accounts.
"The partnerships have been established based on a strong alignment to what we want to achieve for both our advisers and their clients," Hills said. "Our SMA service continues to gather momentum and the combination of this with our platform partners represents a compelling proposition for advisers and their clients alike."
The new service with OneVue is planned to be rolled out in the coming months.
Recommended for you
Research house Genium Investment Partners has appointed a head of investment solutions from Mason Stevens.
ASIC has made two appointments to its senior executive leadership team covering regulation and enforcement following an international search.
Perpetual has reported positive quarterly net inflows for the first time in 12 months, the first under the remit of new chief executive Bernard Reilly.
The global financial services firm has taken on a second AFSL as it looks to capitalise on the high-net-worth market in Australia.
